Assembly Biosciences Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Assembly Biosciences zullen naar verwachting dalen met respectievelijk 44% en 24.1% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 20% per jaar.

Belangrijke informatie

-24.1%

Groei van de winst

-20.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	-44.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

Recent updates

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Nov 13

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Oct 05

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Jul 20

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jun 08

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jan 11

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Sep 03

Assembly Biosciences announces resignation of CFO

Jun 02

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Mar 24

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

Feb 05

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Dec 14

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Nov 16

Assembly Biosciences EPS beats by $0.69, beats on revenue

Nov 05

Winst- en omzetgroeiprognoses

NasdaqGS:ASMB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	16	-87	N/A	N/A	2
12/31/2025	33	-58	N/A	N/A	2
12/31/2024	28	-41	N/A	N/A	1
9/30/2024	28	-41	23	23	N/A
6/30/2024	21	-46	24	24	N/A
3/31/2024	13	-51	28	28	N/A
12/31/2023	7	-61	22	23	N/A
9/30/2023	N/A	-73	-70	-70	N/A
6/30/2023	N/A	-81	-76	-76	N/A
3/31/2023	N/A	-89	-80	-80	N/A
12/31/2022	N/A	-93	-85	-84	N/A
9/30/2022	N/A	-131	-85	-85	N/A
6/30/2022	6	-127	-84	-84	N/A
3/31/2022	6	-126	-88	-88	N/A
12/31/2021	6	-130	-96	-93	N/A
9/30/2021	7	-109	-104	-99	N/A
6/30/2021	36	-94	-75	-70	N/A
3/31/2021	75	-63	-76	-71	N/A
12/31/2020	79	-62	-65	-63	N/A
9/30/2020	83	-50	-59	-58	N/A
6/30/2020	52	-71	-88	-87	N/A
3/31/2020	16	-97	-85	-85	N/A
12/31/2019	16	-98	-86	-84	N/A
9/30/2019	15	-97	-82	-80	N/A
6/30/2019	15	-93	-80	-78	N/A
3/31/2019	15	-102	-75	-73	N/A
12/31/2018	15	-91	-65	-65	N/A
9/30/2018	14	-68	-58	-58	N/A
6/30/2018	13	-58	N/A	-52	N/A
3/31/2018	12	-45	N/A	-49	N/A
12/31/2017	9	-43	N/A	2	N/A
9/30/2017	6	-51	N/A	1	N/A
6/30/2017	3	-51	N/A	4	N/A
3/31/2017	1	-47	N/A	9	N/A
12/31/2016	N/A	-44	N/A	-35	N/A
9/30/2016	N/A	-40	N/A	-29	N/A
6/30/2016	N/A	-36	N/A	-27	N/A
3/31/2016	N/A	-32	N/A	-24	N/A
12/31/2015	N/A	-28	N/A	-19	N/A
9/30/2015	N/A	-27	N/A	-17	N/A
6/30/2015	N/A	-31	N/A	-16	N/A
3/31/2015	N/A	-27	N/A	-13	N/A
12/31/2014	N/A	-24	N/A	-15	N/A
9/30/2014	N/A	-24	N/A	-17	N/A
6/30/2014	N/A	-17	N/A	-18	N/A
3/31/2014	N/A	-20	N/A	-19	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ASMB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ASMB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ASMB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ASMB zal naar verwachting de komende 3 jaar dalen ( -44% per jaar).

Hoge groei-inkomsten: De omzet van ASMB zal naar verwachting de komende 3 jaar dalen ( -44% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ASMB naar verwachting over 3 jaar hoog zal zijn

Assembly Biosciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target decreased to US$7.38

Consensus forecasts updated

Price target increased to US$10.90

Price target decreased to US$9.71

Consensus revenue estimates fall to US$6.63m

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 11%, EPS upgraded

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Assembly Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

New minor risk - Share price stability

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop

Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.

Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024

Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024

Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board

New major risk - Revenue and earnings growth

Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer

New major risk - Share price stability

Assembly Biosciences Receives Non-Compliance Notice from Nasdaq

Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

New major risk - Revenue and earnings growth

Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

New minor risk - Insider selling

Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?

Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

High number of new directors

Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Price target decreased to US$7.38

High number of new directors

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences, Inc. Announces Management Appointments

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Assembly Biosciences, Inc. to Introduce New Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences Inc. Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

High number of new directors

Assembly Biosciences, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Consensus forecasts updated

Price target increased to US$10.90

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.094 loss in 3Q 2020)

Price target decreased to US$9.71

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from Russell Microcap Growth Index

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs At the International Liver Congress™ EASL 2021

CFO & Principal Accounting Officer Thomas Russo has left the company

Assembly Biosciences announces resignation of CFO

Consensus revenue estimates fall to US$6.63m

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Analysts update estimates

Price target lowered to US$11.60

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$6.45

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Assembly Biosciences, Inc. Announces Board Changes, Effective December 31, 2020

Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Analysts increase revenue estimates to US$81.8m

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.094 loss per share

Price target raised to US$49.25

Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Assembly Biosciences EPS beats by $0.69, beats on revenue

Assembly Biosciences, Inc. Announces HBV Core Inhibitor Research and Development Program